EASL 2020

The Digital ILC 2020

August 27—29, 2020

To help you get as much value from Digital ILC as possible, we have identified 15-20 presentations and posters we find most interesting. Our daily podcasts will summarize these and discuss what they suggest for the future of NASH/NAFLD therapies.

Thursday Aug 27, 2020

Our Surfers Discussed The Following Papers and Sessions on Day 1

Roger Green — AS101 Convolutional neural networks of H&E stained biopsy images accurately quantify histologic features of non-alcoholic steatohepatitis

Donna Cryer —  AS098 Machine learning outperforms existing non-invasive tests as a screening tool for liver fibrosis in the general population.

Peter Traber, MD — Session Optimal endpoints in NAFLD clinical Trials: Histology or non-invasive biomarkers and imaging?

Louise Campbell MSc AP — Session Patients for nonalcoholic fatty liver disease referred from primary care have a significant serum fibrosis marker and liver stiffness measurement discordance.

and

AS160: Multidisciplinary team approach to nonalcoholic fatty liver disease improves cardiovascular risk factors

Dr. Stephen Harrison — AS100 Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with non-alcoholic fatty liver disease

Naim Alkhouri, M.D. — AS157 Liver Disease Progression and Clinical Outcomes, and a registry called the, “Hepatic Outcomes and Survival Fatty Liver Registry,” or the “HOTSURFR Study.”

Surfing The NASH Tsunami Podcast Day 1

Friday Aug 28, 2020

Our Surfers Will Discuss The Following Papers and Sessions on Day 2

Today’s Episode Is Sponsored By

Louise Campbell MSc AP — AS064: Incorporating assessment of liver fibrosis into routine diabetic review in primary care or pilot.

Dr. Stephen Harrison — Abstract Session: Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo controlled Phase 2 clinical trial

Donna Cryer —  AS017: A polygenic risk score for progressive nonalcoholic fatty liver disease risk stratification

Roger Green — AS15: Therapeutic effect of a novel long-acting GLP-1, GIP, glucagon triple agonist in animal models of NASH and fibrosis

Peter Traber, MD — Abstract Session: Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: A phase 2 randomized controlled trial (FASCINATE-1)

Vlad Ratziu, MD, PhDM — AS078 EDP-305
A non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a ARGON-1 study

Michael Curry, MD — FRI-050 Assessment of fibrosis and steatosis in patients and healthy volunteers
George Aliphtiras CEO — FRI-050 A 25-minute discussion with George Aliphteras, CEO of Sonic Incytes and Dr. Michael Curry, lead author of poster FRI-050, which discusses Velacur
Sonic Incytes is on a mission to reduce chronic liver disease by enabling routine assessment and management of liver health. Its breakthrough, point of care ultrasound solution, Velacur™, assesses and manages chronic liver disease with diagnostic accuracy that is comparable to MRI. Learn more: www.sonicincytes.com

Saturday, Aug 29, 2020

Our Surfers Discussed The Following Papers and Sessions on Day 3

Donna Cryer —  AS018: Carbohydrate restriction reverses NAFLD by altering hepatic mitochondrial fluxes in humans.

Louise Campbell MSc AP — SAT249: The variscreen algorithm using successively platelets, liver stiffness, and INR improves and secures the screening of esophageal varies needing treatment.

Peter Traber, MD — LB004: Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

Dr. Stephen Harrison — LB001: Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis

Roger Green — Covid and the Liver: Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis

Prof. Dr. Jörn M. Schattenberg — LBP01 Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)

Surfing The NASH Tsunami Podcast Day 3

Available In Your Favorite Podcast App:

Apple
Spotify
Google
Stitcher
SoundCloud
YouTube
Buzzsprout